title: [Application of half-dose depot long-acting triptorelin in postoperative adjuvant therapy for endometriosis].
abstract: OBJECTIVE
  To evaluate the efficacy and adverse effects of half-dose depot long-acting triptorelin in the therapy of endometriosis.
  
  
  METHODS
  The efficacy and adverse effects of routine-dose or half-dose triptorelin in postoperative endometriosis patients were prospectively observed. A total of 186 postoperative patients with moderate or severe endometriosis received an intramuscular injection of triptorelin every 28 days for 6 times. They were randomly divided into 3 groups, i.e. half-dose group (n = 99): 1.875 mg each time; "draw-back" group (n = 52): 3.75 mg first time, then 1.875 mg each time; and routine-dose group (n = 35): 3.75 mg each time.
  
  
  RESULTS
  Amenorrhea was effectively induced in all patients after the second injection. There was no significant difference in the rate of serum E2 level at Day 28 of every injection below the upper limit of "estrogen threshold (110 - 146 pmol/L)" not stimulating ectopic endometrium proliferation among half-dose group, "draw-back" group and routine-dose group (99% vs 100% and 99.0%, P > 0.05), the percentage of E2 < 37 pmol/L in E2 < 110 pmol/L in half-dose group was significantly lower than that in "draw-back" and routine-dose groups after 2-5(th) injection (69% vs 79% and 85%, P < 0.01), but there was no significant difference after first half-dose and routine-dose injection (71% vs 73%, P > 0.05). No significant difference existed in the rate of pelvic pain relief during the first returning menstruation and the recurrence rate of endometriosis within 1 year postoperation among three groups (both P > 0.05). However, the incidences of menopausal syndrome and severe menopausal syndrome in half-dose group were significantly lower than those in "draw-back" and routine-dose groups (both P < 0.01). And the incompletion rate of six-time drug for severe menopause syndrome was also significantly lower (P < 0.05) while the completion rate of six-time drug use in half-dose group was significantly higher (P < 0.05).
  
  
  CONCLUSIONS
  As a postoperative adjuvant, half-dose depot triptorelin therapy is efficacious for endometriosis. It reduces menopausal syndrome and treatment cost and enhances patient compliance.
authors.affiliation: Department of Centre for Reproductive Medicine & Infertility, Jiaxing, China. sunglow6@hotmail.com
authors.forename: Xia
authors.initials: X
authors.lastname: Liu
authors.forename: Hong-xia
authors.initials: HX
authors.lastname: Zhang
authors.forename: Li-ping
authors.initials: LP
authors.lastname: Wang
authors.forename: Wei-ping
authors.initials: WP
authors.lastname: Fu
mesh_terms: D000328:Adult; D003131:Combined Modality Therapy; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011184:Postoperative Period; D011446:Prospective Studies; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000008:administration & dosage* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D017329:Triptorelin Pamoate